WHO’s New Obesity Guidelines Explained: Why GLP1 Drugs Need More Than Medicine
In December 2025, the World Health Organization released its first-ever global guideline on using GLP1 therapies to treat obesity. This marks a major shift: obesity is now recognised as a chronic disease that needs lifelong, compassionate care.
The guideline covers medicines like:
- Semaglutide
- Liraglutide
- Tirzepatide
These drugs help reduce appetite, slow digestion, improve metabolism, and support sustained weight loss. But the WHO is clear: medicines alone are not enough.
What the guideline recommends
Use GLP1 drugs only as part of a longterm obesity care plan
Combine medication with:
- healthy eating
- regular physical activity
- behavioural support (counselling, structured diet plans, exercise guidance, followups)
Build health systems that ensure fair, affordable, and respectful access
Personalise treatment based on people’s needs and circumstances
What we still don’t know
- Longterm safety and what happens when medicines stop
- How to maintain weight loss
- How countries will ensure supply and affordability
Why it matters
This guideline offers a more humane, sciencebacked approach to obesity treatment. It recognises that millions of people need longterm support, not shortterm fixes or stigma.
If you want to understand how the world’s view on obesity is changing, and what these new WHO recommendations mean for patients, doctors, and health systems — this video breaks it down clearly.